Cargando…

BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma

BACKGROUND: Genetic alterations in chromatin modulators such as BRCA-1 associated protein-1 (BAP1) are the most frequent genetic alteration in intrahepatic cholangiocarcinomas (CCA). We evaluated the contribution of BAP1 expression on tumor cell behavior and therapeutic sensitivity to identify ratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Parasramka, Mansi, Yan, Irene K., Wang, Xue, Nguyen, Phuong, Matsuda, Akiko, Maji, Sayantan, Foye, Catherine, Asmann, Yan, Patel, Tushar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264287/
https://www.ncbi.nlm.nih.gov/pubmed/28122578
http://dx.doi.org/10.1186/s12943-017-0587-x
_version_ 1782500074791632896
author Parasramka, Mansi
Yan, Irene K.
Wang, Xue
Nguyen, Phuong
Matsuda, Akiko
Maji, Sayantan
Foye, Catherine
Asmann, Yan
Patel, Tushar
author_facet Parasramka, Mansi
Yan, Irene K.
Wang, Xue
Nguyen, Phuong
Matsuda, Akiko
Maji, Sayantan
Foye, Catherine
Asmann, Yan
Patel, Tushar
author_sort Parasramka, Mansi
collection PubMed
description BACKGROUND: Genetic alterations in chromatin modulators such as BRCA-1 associated protein-1 (BAP1) are the most frequent genetic alteration in intrahepatic cholangiocarcinomas (CCA). We evaluated the contribution of BAP1 expression on tumor cell behavior and therapeutic sensitivity to identify rationale therapeutic strategies. METHODS: The impact of BAP1 expression on sensitivity to therapeutic agents was evaluated in CCA cells with a 7-fold difference in BAP1 expression (KMBC-low, HuCCT1-high) and genetically engineered haplo-insufficient BAP1 knockout cells. We also identified long non-coding RNA genes associated with loss of BAP1 and their role in therapeutic sensitivity. RESULTS: Sensitivity to gemcitabine was greater in low BAP1 expressing or BAP1 knockout cells compared with the high BAP1 expressing cells or control haplo-insufficient cells respectively. Similar results were observed with TSA, olaparib, b-AP15 but not with GSK126. A differential synergistic effect was observed in combinations of gemcitabine with olaparib or GSK126 in KMBC cells and TSA or bAP15 in HuCCT1 cells, indicating BAP1 dependent target-specific synergism and sensitivity to gemcitabine. A BAP1 dependent alteration in expression of lncRNA NEAT-1 was identified by RT-PCR based lncRNA expression profiling, and an inverse relationship between this lncRNA and BAP1 was observed in analysis of the Tumor Cancer Genome Atlas cholangiocarcinoma dataset. Exogenous modulation of NEAT-1 and/or BAP1 expression altered tumor cell phenotype and modulated sensitivity to gemcitabine. CONCLUSIONS: NEAT-1 is a downstream effector of gemcitabine sensitivity in CCA. The expression of BAP1 is a determinant of sensitivity to therapeutic drugs that can be exploited to enhance responses through combination strategies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-017-0587-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5264287
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52642872017-01-30 BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma Parasramka, Mansi Yan, Irene K. Wang, Xue Nguyen, Phuong Matsuda, Akiko Maji, Sayantan Foye, Catherine Asmann, Yan Patel, Tushar Mol Cancer Research BACKGROUND: Genetic alterations in chromatin modulators such as BRCA-1 associated protein-1 (BAP1) are the most frequent genetic alteration in intrahepatic cholangiocarcinomas (CCA). We evaluated the contribution of BAP1 expression on tumor cell behavior and therapeutic sensitivity to identify rationale therapeutic strategies. METHODS: The impact of BAP1 expression on sensitivity to therapeutic agents was evaluated in CCA cells with a 7-fold difference in BAP1 expression (KMBC-low, HuCCT1-high) and genetically engineered haplo-insufficient BAP1 knockout cells. We also identified long non-coding RNA genes associated with loss of BAP1 and their role in therapeutic sensitivity. RESULTS: Sensitivity to gemcitabine was greater in low BAP1 expressing or BAP1 knockout cells compared with the high BAP1 expressing cells or control haplo-insufficient cells respectively. Similar results were observed with TSA, olaparib, b-AP15 but not with GSK126. A differential synergistic effect was observed in combinations of gemcitabine with olaparib or GSK126 in KMBC cells and TSA or bAP15 in HuCCT1 cells, indicating BAP1 dependent target-specific synergism and sensitivity to gemcitabine. A BAP1 dependent alteration in expression of lncRNA NEAT-1 was identified by RT-PCR based lncRNA expression profiling, and an inverse relationship between this lncRNA and BAP1 was observed in analysis of the Tumor Cancer Genome Atlas cholangiocarcinoma dataset. Exogenous modulation of NEAT-1 and/or BAP1 expression altered tumor cell phenotype and modulated sensitivity to gemcitabine. CONCLUSIONS: NEAT-1 is a downstream effector of gemcitabine sensitivity in CCA. The expression of BAP1 is a determinant of sensitivity to therapeutic drugs that can be exploited to enhance responses through combination strategies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-017-0587-x) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-25 /pmc/articles/PMC5264287/ /pubmed/28122578 http://dx.doi.org/10.1186/s12943-017-0587-x Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Parasramka, Mansi
Yan, Irene K.
Wang, Xue
Nguyen, Phuong
Matsuda, Akiko
Maji, Sayantan
Foye, Catherine
Asmann, Yan
Patel, Tushar
BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma
title BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma
title_full BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma
title_fullStr BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma
title_full_unstemmed BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma
title_short BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma
title_sort bap1 dependent expression of long non-coding rna neat-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264287/
https://www.ncbi.nlm.nih.gov/pubmed/28122578
http://dx.doi.org/10.1186/s12943-017-0587-x
work_keys_str_mv AT parasramkamansi bap1dependentexpressionoflongnoncodingrnaneat1contributestosensitivitytogemcitabineincholangiocarcinoma
AT yanirenek bap1dependentexpressionoflongnoncodingrnaneat1contributestosensitivitytogemcitabineincholangiocarcinoma
AT wangxue bap1dependentexpressionoflongnoncodingrnaneat1contributestosensitivitytogemcitabineincholangiocarcinoma
AT nguyenphuong bap1dependentexpressionoflongnoncodingrnaneat1contributestosensitivitytogemcitabineincholangiocarcinoma
AT matsudaakiko bap1dependentexpressionoflongnoncodingrnaneat1contributestosensitivitytogemcitabineincholangiocarcinoma
AT majisayantan bap1dependentexpressionoflongnoncodingrnaneat1contributestosensitivitytogemcitabineincholangiocarcinoma
AT foyecatherine bap1dependentexpressionoflongnoncodingrnaneat1contributestosensitivitytogemcitabineincholangiocarcinoma
AT asmannyan bap1dependentexpressionoflongnoncodingrnaneat1contributestosensitivitytogemcitabineincholangiocarcinoma
AT pateltushar bap1dependentexpressionoflongnoncodingrnaneat1contributestosensitivitytogemcitabineincholangiocarcinoma